IXICO selected as EPAD imaging analysis partner

RNS Number : 3232C

IXICO plc

16 January 2015

 



IXICO plc

IXICO selected as imaging analysis partner within The European Prevention of Alzheimer's dementia Initiative (EPAD)

16 January 2015, IXICO plc (Ticker: IXI) ("IXICO" or the "Company"), the brain health company, announces today its selection as a partner within The European Prevention of Alzheimer's dementia Initiative (EPAD), a novel collaboration between academic and private sectors to test innovative treatments for the secondary prevention of Alzheimer's dementia.

The 5-year programme is part of the Innovative Medicines Initiative (IMI), a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, (EFPIA). EPAD will establish a European-wide register of 24,000 participants, of which 1,500 will be invited to participate in trials to test new treatments for prevention of Alzheimer's dementia.

As part of this programme, IXICO will provide its TrialTracker™ platform to collect and manage imaging data in combination with its Assessa medical device to identify subjects who are most likely to benefit from treatment.

Background to the EPAD programme

Previous attempts to bring new drugs for Alzheimer's disease to the market have been disappointing despite a high level of investment. However, the realisation that Alzheimer's disease is a progressive disorder and that early intervention may be more effective has led to research efforts being focused on prevention. The goal of the initiative is the prevention of dementia in people with evidence of the disease (such as biomarker abnormalities as identified by specific tests), who still may have little or no complaints or clinical symptoms. New tools and methods now allow the identification of patients in the early stages of Alzheimer's disease. This creates an opportunity to have new treatment options investigated in clinical studies early on. A difficulty however remains with the large number of patients and study sites needed to confirm a therapeutic effect within a limited span of time. In contrast to several pharmaceutical companies and academic institutions pursuing this in isolation, a joint effort clearly has advantages: the identification and referral of the concerned patients is accelerated and several treatment options can be tested rapidly within one same trial. Therefore, EPAD aims to develop a platform using existing information from national or regional patient cohorts or register studies, which have already identified potential patients. Through EPAD, the undertaking of better, adaptive, multi-arm proof of concept studies for early and accurate decisions on the ongoing development of drug candidates or drug combinations is facilitated. All data collected from the cohort and trial will become publically available for analysis to improve disease models in the pre-dementia phase of Alzheimer's disease.

Professor Craig Ritchie, EPAD Co-coordinator and Professor of the Psychiatry of Ageing at the University of Edinburgh, said:

"EPAD is part of a global initiative that will make a fundamental difference to the understanding and management of Alzheimer's disease in people with very early or no symptoms at all. This could be a game-changer. It is only possible because of the absolute commitment of academics, industry, policy makers and the public to work hand in hand to defeat this global threat."

Jean Georges, Executive Director of Alzheimer Europe, said:

"Preventing the development of dementia in biomarker-positive people would be a fantastic step forward in our fight against Alzheimer's disease. The EPAD and its novel trial concept will hopefully help speed up the drug discovery progress and bring us closer to this ambitious aim."

Derek Hill, CEO of IXICO said:

"We are extremely pleased to join distinguished academic and industry specialists in this ground-breaking pan-European initiative and look forward to working with our colleagues to help improve the prevention, diagnosis and management of dementia."

About IXICO

IXICO, the brain health company, uses its innovative and proprietary digital platform technologies to help those involved in researching and treating serious diseases to make rapid decisions and improve patient outcomes.  Established since 2004, IXICO has significant experience in working with global pharmaceutical and biotechnology companies in dementia clinical studies and other neuro-degenerative disorders including Huntington's disease and Multiple Sclerosis.

For more information about IXICO, please visit www.ixico.com

About EPAD

The EPAD project is part of a global effort in the fight against Alzheimer's disease, which also includes initiatives such as the Global Alzheimer Platform. The EPAD Project is a major European initiative to create a novel environment for testing numerous interventions targeted at the prevention of Alzheimer's dementia defined as a delay in the onset of clinical symptoms among people with preclinical evidence for AD pathology (i.e. preclinical AD as per NIA-AA and similar definitions) and a delay in the onset of clinical dementia among people with such evidence who already show some clinical symptoms (i.e. MCI due to AD or prodromal AD and similar definitions).

EPAD is mainly sponsored by the European Commission and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative Joint Undertaking (IMI JU). The EPAD programme has an initial budget of €64M distributed across a total of 35 partners from the private and academic sectors:

·     Janssen Pharmaceutica NV, Belgium ·     University of Edinburgh, United Kingdom ·     University of Oxford, United Kingdom ·     Barcelonabeta Brain research Centre at Pasqual Maragall Foundation, Spain ·     Synapse Research Management Partners SL, Spain ·     Karolinska Institutet, Center For Alzheimer's Disease Research, Sweden ·     Stichting VU-VUmc, Netherlands ·     University of Cambridge, United Kingdom ·     Medical Research Council Biostatistics Unit, United Kingdom ·     Berry Consultants LLP, United Kingdom ·     Université de Genève, Switzerland ·     Radboud University Medical Centre, Netherlands ·     Cardiff University, United Kingdom ·     Centre Hospitalier Universitaire de Toulouse, France ·     Quintiles, LTD, United Kingdom ·     Alzheimer Europe, Luxembourg ·     Erasmus Universitair Medisch Centrum Rotterdam, Netherlands

·     Hôpital de la Salpêtrière, France ·     Institut national de la santé et de la recherche médicale, France ·     University of Leicester, United Kingdom ·     IXICO Technologies Ltd, United Kingdom ·     Araclon Biotech, S.L., Spain ·     Fraunhofer, Germany ·     Eisai Inc., United States ·     Sanofi-Aventis Recherche & Développement, France ·     Novartis Pharma AG, Switzerland ·     Boehringer Ingelheim International GmbH, Germany ·     Ely Lilly and Company Ltd, United Kingdom ·     Lundbeck A/S, Denmark ·     Takeda Development Centre Europe Ltd, United Kingdom ·     AC Immune SA, Switzerland ·     Biogen Idec Inc., United States ·     Amgen NV, Belgium ·     Pfizer Limited, United Kingdom ·     UCB Biopharma SPRL, Belgium

The project is divided into eight Work Packages with four Scientific Advisory Groups. The trial will be delivered through approximately 30 study sites within six country/regional areas.

While the EPAD platform will be designed to help testing both pharmacological and non-pharmacological interventions, initially the focus will be on testing drugs and drug combinations to ensure a greater chance of success for clinical trials. The EPAD programme will initially run for five years.

For more information, contact [e-mail] or visit www.ep-ad.org

About the EPAD Platform/Register

EPAD aims to develop a platform using existing information. The EPAD platform will draw European participants, whose records are already part of existing national/regional cohort or register studies, into an EPAD register of approximately 24,000 people. From this group, 6,000 people will be asked to join a pan-European EPAD Cohort for consistent, longitudinal follow-up, and approximately 1,500 of them will eventually be invited to enter the EPAD Proof of Concept Trial. This approach aims to ensure EPAD has access to an at-risk population showing biomarker evidence of Alzheimer's disease prior to the development of dementia.

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

More information can be found at www.imi.europa.eu

Acknowledgement

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.

Enquiries:                                    

IXICO plc                               

Derek Hill, CEO

Susan Lowther, Chief Financial Officer

Charles Spicer, VP Corporate Development                         

UK Headquarters:  Griffin Court, 15 Long Lane London EC1, United Kingdom

[phone]

US Office: Building D-1, 220 Union Square Drive, New Hope, Pennsylvania, US

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel

Clare Terlouw

[phone]

Daniel Stewart & Company (Joint Broker)

Mark Treharne

[phone]

FTI Consulting Limited (Investor Relations)

Ben Atwell

Simon Conway

[phone]

 

END

 

 

MSCBRGDBLDBBGUU